Anthera Pharma (ANTH) Tops Q4 EPS by 10c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/13/2026
- S&P 500 notches record-high close as rate-hike worries ease
- Oil settles down 2% on weak demand outlook, hefty US crude build
- BofA lifts server CPU TAM to $210bn+ on the rise of AI agents
- Burry doubles down on Nebius short after stock surges 34% on earnings
- JPMorgan gets bullish on Salesforce, says concerns are "overblown"
Anthera Pharmaceuticals Provides Business Update and Reports 2015 Fourth Quarter and Fiscal Year Financial Results
March 10, 2016 8:37 AM ESTSOLUTION clinical study of oral Sollpura enrollment to begin soon in EuropeData from BRIGHT-SC study in IgA nephropathy planned for Q2 2016Addition of Craig Thompson as President and Chief Operating OfficerAppointment of Dr. James Pennington to Interim Chief Medical Officer
HAYWARD, Calif., March 10, 2016 (GLOBE NEWSWIRE) -- Anthera Pharmaceuticals, Inc. (Nasdaq: ANTH) today provided a business update and reported financial results for the fourth quarter and year ended December 31, 2015.
Recent Developments and Business Highlights:
Clinical Development
... More